This research evaluates antibiotic activity in Emericellopsis sp. E102, revealing its potential for new antibacterial compounds.
In recent decades, the interest in Emericellopsis genus as producers of bioactive molecules has increased significantly due to the isolation of new compounds with potential pharmaceutical applications. Evaluation of the spectrum of antibiotic activity has allowed us to choose a promising producer of new antibacterial compound, Emericellopsis sp. E102 strain derived from saline soils. Strain E102, based on molecular and phylogenetic constructions, is allocated to a separate clade within the marine clade of Emericellopsis and is presumably a new species. The ethyl acetate extract of E102 strain demonstrated significant efficacy in a concentration of 1.000 µg/mL, resulting in inhibition zones measuring 20.3–30.0 mm against Escherichia coli ATCC 25922; Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212. The high-performance liquid chromatography analysis identified compound with monoisotopic mass of the substance 724.5 g/mol. Using the Chemcalc.org service, the most probable gross formulas of the required component were determined. Based on the presented calculations, there is a high probability that the substance has a sterane framework.
No takes yet. Share an insight, caveat, or question.
Sokolov et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: